Ludwig Lausanne

Company

Also known as: Ludwig Lausanne

Related News

Researchers Advance CAR T-Cell Safety with Remote Control and Risk Prediction Studies

Feb 25, 2026

New research addresses CAR T-cell therapy safety through a venetoclax-controlled on-off switch and a prospective study identifying neurotoxicity risk markers in pediatric patients with acute lymphoblastic leukemia.

Scientists Engineer CAR-T Cells to Target Amyloid in Alzheimer's Disease

Feb 19, 2026

Researchers at Washington University in St. Louis have adapted CAR-T immunotherapy to target aggregated amyloid-beta in mice, with transient CAR expression clearing brain plaques. The approach uses CD4+ T cells engineered with receptors based on lecanemab antibody sequences.